📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

The p38 mitogen activated protein kinase inhibitor losmapimod in chronic obstructive pulmonary disease patients with systemic inflammation, stratified by fibrinogen: A randomised double-blind placebo-controlled trial. (2018)

First Author: Fisk M

Attributed to: Developmental Clinical Studies - ACE inhibitors to augment the effects of pulmonary rehabilitation in COPD funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1371/journal.pone.0194197

PubMed Identifier: 29566026

Publication URI: http://europepmc.org/abstract/MED/29566026

Type: Journal Article/Review

Volume: 13

Parent Publication: PloS one

Issue: 3

ISSN: 1932-6203